Ainos Initiates Live AI Nose Deployments within Semiconductor Manufacturing Environments
Rhea-AI Summary
Ainos (NASDAQ:AIMD) began live AI Nose deployments in semiconductor manufacturing after receiving an initial $2.1 million order from a back-end packaging and testing customer. Preparations in the second half of 2025 enabled on-site rollouts that started in January 2026.
Back-end deployments are now operating in live environments generating scent data, while front-end semiconductor pilots advance to broaden use cases and strengthen Ainos' Smell Language Model (SLM).
AI-generated analysis. Not financial advice.
Positive
- $2.1M initial commercial order from a back-end semiconductor customer
- Live back-end deployments began in January 2026, marking first commercial execution
- Front-end pilots advancing to expand use cases across the semiconductor value chain
- SLM data flywheel strengthened by continuous real-world scent data from live operations
Negative
- Commercial deployments currently tied to a single initial customer/order
- Front-end activity remains at pilot stage, not yet commercial deployments
News Market Reaction – AIMDW
On the day this news was published, AIMDW gained 34.26%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Back-end semiconductor deployments begin under initial customer order
Front-end semiconductor pilots advance across targeted environments
HOUSTON, TEXAS / ACCESS Newswire / February 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced the start of AI Nose deployments tied to its first
During the second half of 2025, Ainos carried out deployment readiness preparations. This groundwork positioned the AI Nose platform for live environments.
Back-end Deployments Enter Live Operation
In January 2026, Ainos commenced on-site deployments associated with its initial
Front-End Pilots Advancing
In parallel, Ainos is advancing pilot programs across targeted front-end semiconductor environments to support broader use-case expansion within the semiconductor value chain.
"2025 was about ensuring we were ready to scale in real manufacturing settings," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "With back-end commercial deployments now underway, we are operating in live environments that continuously generate real-world scent data, while front-end semiconductor programs continue to build momentum. As these programs scale, we are strengthening our Smell Language Model (SLM) and reinforcing the data flywheel that underpins the AI Nose platform-positioning smell as the next machine-readable token for AI."
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.
Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Investor Relations Contact
Feifei Shen
Email: IR@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire